Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02)

NCT00505232 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Y-90 Ibritumomab tiuxetan

Sponsor

CABYC

Collaborators

[object Object]